Zydelig (Idelalisib) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up Log in
About MyLymphomaTeam
Powered By

Zydelig is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat relapsed cases of follicular B-cell non-Hodgkin lymphoma, small lymphocytic lymphoma (SLL), and chronic lymphocytic leukemia (CLL). Zydelig is used in cases where other therapies have already been tried. In cases of CLL, Zydelig is usually combined with rituximab (Rituxan). Zydelig is also referred to by its drug name, idelalisib.

Zydelig is used as targeted therapy for lymphoma. Zydelig is a member of a class of drugs called kinase inhibitors. Zydelig is believed to work by inhibiting normal cellular functions, resulting in lymphoma cell death.

How do I take it?
Prescribing information states that Zydelig is taken orally twice daily.

Zydelig comes in the form of a tablet.

Side effects
The FDA-approved label for Zydelig lists common side effects including fever, fatigue, cough, rash, nausea, abdominal pain, and pneumonia. Severe infections, diarrhea, intestinal inflammation, and liver damage are common and potentially life-threatening side effects in those who take Zydelig.

Rare but serious side effects listed for Zydelig include intestinal perforations and lung inflammation.

For more details about this treatment, visit:

Zydelig – Gilead

Lymphoma — Non-Hodgkin: Types of Treatment — Cancer.Net

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in